The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in ...

Researchers hope to soon commercialize a simple, inexpensive, and accessible screening test that uses taste as a detection ...

As the shutdown drags out, there could be delays in regulatory processes and payments for medical services as well as the ...

Regulatory burdens have raised the capital requirements for early-stage companies, causing many to do what would have been ...

NEW YORK – Digital pathology firm Aiforia said on Wednesday that it has forged an agreement with Siemens Healthineers for the comarketing and sales in Finland of Aiforia's artificial ...

The company noted that if PAMA cuts go into effect at the beginning of next year as scheduled, they would negatively impact its 2026 revenues by around $100 million.

360Dx regularly updates this tracker to provide readers with accurate information on the regulatory status of these tests in the US, European, and Asian markets.

The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.

The private equity firms expect to close the deal in the first half of 2026 with a valuation of up to $79 per share.

The firm's diagnostics revenues rose 4 percent to $2.46 billion, partially due to the growth of respiratory disease testing-related revenues from Cepheid.

Last week, readers were most interested in a story about alternatives to blood as sample types for diagnostic testing.